Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for the three months ended September 30, 2026.
Amphastar Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for the three months ended September 30, 2026
- Investor focus: revenue, profitability, product performance and outlook in the referenced earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net revenues $207.6M, up 8%, led by BAQSIMI $58.8M and Primatene MIST $31.5M
- GAAP net income $37.8M, or $0.87 diluted EPS, versus $17.4M and $0.37 in Q3 2025
- Gross margin fell to 48.0% from 51.4%, pressured by pricing, IMS remediation costs, and facility expansion
- Epinephrine sales declined 19% and glucagon 37%, highlighting pricing, supply, and remediation-related product risks
- $50M share-buyback authorization increase, primarily to offset equity-compensation dilution; operating cash flow reached $142.5M year-to-date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amphastar Pharmaceuticals, Inc. 8-K filings
Get the next AMPH 8-K as it lands
Follow AMPH for push alerts, or ask the research agent what this filing means.